Effect of Diane-35 treatment on metabolism and sex hormone in women with polycystic ovary syndrome

doi:10.3969/j.issn.1006-7795.2019.04.013

Abstract

Abstract: Objective To determine the effects of Diane-35 on body composition, glycolipid metabolism and liver and kidney function in patients with polycystic ovary syndrome (PCOS), and to analyze its efficacy and safety.Methods Totally 59 patients with polycystic ovary syndrome were enrolled in this study. Diane-35 was prescribed to them for 3 cycles. After 3 cycles, self-control was conducted, and the monitoring indicators were anthropometric indicators and blood pressure, sugar and lipid metabolism, sex hormone, liver and kidney function.Results Body weight, body mass index (BMI), waist circumference (WC), and hip circumference (HC) were significantly lower than those before pretreatment, while systolic blood pressure (SBP) and diastolic blood pressure (DBP) had no statistical difference. For sugar and lipid metabolism, there was no significant difference in total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), fasting blood glucose (FBG), fasting insulin (FINS) and homeostasis model insulin resistance index (HOMA-IR), fat distribution and percentage of fat. For sex hormone related indicators showed as follow:serum luteinizing hormone (LH), and free androgen index (FAI) decreased significantly; sex hormone binding globulin (SHBG) increased significantly; while total testosterone (TT), dehydroepiandrosterone sulfate (DHEA-S), androstenedione (AND), free testosterone (FT), serum follicle stimulating hormone (FSH) levels were not significantly different. For liver and kidney function:blood urea nitrogen (BUN) was decreased, but there was no significant difference in serum creatinine (Cr), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT). Conclusion Oral contraceptive pretreatment may have a weight-loss effect on PCOS patients, with no significant effect on blood pressure. It can reduce LH level, increase SHBG level and exert the biological effect of inhibiting androgen. Short-term oral contraceptives have no significant effect on liver and kidney function suggesting high safty.

Key words: polycystic ovary syndrome (PCOS), Diane-35, metabolism

CLC Number:

R711.75

Gu Muqing, Li Yanglu, Cheng Jiaojiao, Wang Husheng, Ruan Xiangyan, Jia Chanwei. Effect of Diane-35 treatment on metabolism and sex hormone in women with polycystic ovary syndrome[J]. Journal of Capital Medical University, 2019, 40(4): 560-565.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.04.013

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I4/560

References 22

[1]	张多加, 常惠, 沈文娟, 等. 多囊卵巢综合征患者的肥胖和代谢功能障碍[J]. 国际妇产科学杂志, 2018, 45(2):184-187.
[2]	丁风娟, 郝翠芳. 多囊卵巢综合征患者胰岛素抵抗的研究进展[J]. 生殖医学杂志, 2019,28(3):315-319.
[3]	Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome[J]. Fertil steril, 2004, 81(1):19-25.
[4]	金婧, 阮祥燕, 华琳, 等. 多囊卵巢综合征卵巢储备功能降低患者肥胖及糖脂代谢特征[J]. 首都医科大学学报, 2018,39(4):33-39.
[5]	武红琴, 阮祥燕, 卢永军,等. 多囊卵巢综合征患者合并代谢综合征的患病率和预测指标[J]. 首都医科大学学报, 2015, 36(4):553-558.
[6]	Orbetsova M, Kamenov Z, Kolarov G, et al. Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy[J]. Akush Ginekol(sofiia), 2006, 45(7):16-28.
[7]	武红琴,阮祥燕,卢永军,等. 综合管理下达英-35与达英-35联合二甲双胍治疗多囊卵巢综合征的疗效研究[J]. 首都医科大学学报, 2014, 35(4):407-413.
[8]	Phillips N, Duffy T. One-hour glucose tolerance in relation to the use of contraceptive drugs[J]. Am J Obstet Gynecol, 1973, 116(1):91-100.
[9]	Escobar-Morreale H F, Lasunción M A, Sancho J. Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity[J]. Fertil Steril,2000,74(4):816-819.
[10]	Lubianca J N, Moreira L B, Gus M, et al. Stopping oral contraceptives:an effective blood pressure-lowering intervention in women with hypertension[J]. J Hum hypertens, 2005, 19(6):451-455.
[11]	Williams B, Mancia G, Spiering W, et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension[J]. Blood Pressure, 2018,27(6):314-340.
[12]	Escobar-Morreale H F, San Millán J L. Abdominal adiposity and the polycystic ovary syndrome[J]. Trends Endocrinol Metab, 2007, 18(7):266-272.
[13]	李扬璐, 阮祥燕, 赵越, 等.达英-35卵巢综合征患者糖脂代谢的影响[J]. 首都医科大学学报,2016,37(4):424-430.
[14]	Godsland I F. Biology:risk factor modification by OCs and HRT lipids and lipoproteins[J]. Maturitas, 2004, 47(4):299-303.
[15]	Luque-RamiÍrez M, Alvarez-Blasco F, Botella-Carretero J I, et al. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2007, 92(7):2453-2461.
[16]	Yılmaz M, Bukan N, Ersoy R, et al. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome[J]. Hum Reprod, 2005, 20(9):2414-2420.
[17]	Ehrmann D A, Barnes R B, Rosenfield R L, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome[J].Diabetes care,1999,22(1):141-146.
[18]	不同胰岛素抵抗及肥胖水平对多囊卵巢综合征患者高雄激素血症特征的影响[J]. 广东医学, 2017, 38(3):406-409.
[19]	杨毅. 多囊卵巢综合征患者血清抗苗勒氏管激素水平与胰岛素抵抗及雄激素的相关性研究[J].解放军医药杂志,2018,30(4):72-74.
[20]	李立峰, 王晓艳, 姜健慧. 达英-35联合二甲双胍对肥胖型多囊卵巢综合征患者性激素水平、胰岛功能及脂肪因子的影响[J]. 中国妇幼保健, 2018, 33(1):48-50.
[21]	Pasquali R, Gambineri A. Glucose intolerance states in women with the polycystic ovary syndrome[J]. J Endocrinol Invest, 2013, 36(8):648-653.
[22]	Morin-papunen L C, Vauhkonen I, Koivunen R M, et al. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome:a randomized study[J]. J Clin Endocrinol Metab, 2000, 85(9):3161-3168.